MetaCap

Cadrenal Therapeutics Inc. (CVKD)

NASDAQ: CVKDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.70+0.01 (+0.59%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CVKD stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$3.67
52-week range
0.816 – 12.50
Day range
1.52 – 1.85
Volume / Avg
206.57K / 496.14K
Beta
—
Next earnings
Nov 23, 2026

52-week range

$0.816$12.50

CVKD stock today

Shares of Cadrenal Therapeutics (CVKD) finished higher on Nov 20 at $1.70, a gain of 0.59% or $0.01 per share, versus the S&P 500's 3.70% decline. Trading was light, with 206.57K shares changing hands, about 42% of the average daily volume. At this level, CVKD sits near the bottom of its 52-week range of $0.816 to $12.50: 86.4% below the high and 108.3% above the low.

Cadrenal Therapeutics has posted a net loss over the last twelve months (EPS of -$3.67), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Nov 23; analysts expect EPS of -$0.91.

Summary generated from market data by MetaCap's automated system. Methodology

About Cadrenal Therapeutics

Company profile

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Quang X. Pham
Headquarters
Ponte Vedra, FL
Employees
5
IPO year
2023

Financial highlights

Full financials

Cadrenal Therapeutics reported a net loss of $13.2 million, compared with a loss of $10.7 million a year earlier. Diluted earnings per share came in at -$6.64.

Cadrenal Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue———
Growth———
Net income$-13.24M$-10.65M$-8.36M
EPS (diluted)$-6.64$-8.73$-9.29

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$14.00+723.53%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $17.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Nov 23, 2026
EPS estimate
$-0.91
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-1.31 vs $-0.91
Surprise
-43.96%

Cadrenal Therapeutics peers

Health Care sector
CVKD peer companies
CompanyPrice% ChgMarket capCompare
TCRTAlaunos Therapeutics Inc.1.66+3.75%$6.99Mvs CVKD
ENSCEnsysce Biosciences Inc.0.36-0.17%$7.00Mvs CVKD
CURXCuranex Pharmaceuticals Inc4.41-0.67%$6.92Mvs CVKD
MTVAMetaVia Inc.1.01-7.34%$6.81Mvs CVKD
IMRNImmuron Limited ADR0.8998+5.80%$7.26Mvs CVKD
BFRGBullfrog AI Holdings Inc.0.3556-8.84%$6.65Mvs CVKD
RKTORocket One Inc.0.297+5.24%$7.39Mvs CVKD
VTGNVistagen Therapeutics Inc.0.1636-12.33%$7.56Mvs CVKD

Indexes, lists and sector

Cadrenal Therapeutics stock FAQ

What is Cadrenal Therapeutics's stock price today?

CVKD last traded at $1.70 as of Nov 20, 4:00 PM EST, up 0.59% on the day. Prices are delayed at least 15 minutes.

When is Cadrenal Therapeutics's next earnings date?

Cadrenal Therapeutics is expected to report earnings on Monday, November 23, 2026. Analysts expect EPS of $-0.91.

Who is Cadrenal Therapeutics's CEO?

Mr. Quang X. Pham is the chief executive officer of Cadrenal Therapeutics Inc., which has about 5 employees.

What is the CVKD 52-week high?

The 52-week high for CVKD is $12.50 and the 52-week low is $0.816. The stock is currently 86.4% below its high.

Compare CVKD